MIA-606

1 study on MIA-606 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.

Bottom line: TitrateLab currently curates 1 dated study on MIA-606. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.

MIA-606 studies and clinical research

2026-04-03 PubMed

GHRH-R antagonists MIA-602, MIA-606, and MIA-690 inhibit prostate cancer progression by inducing apoptosis and reducing proliferation.

This in vitro research provides strong preclinical evidence for a new class of compounds in the fight against **prostate cancer**. The results suggest that GHRH-R antagonists like the `MIAMI` series could be a powerfu…

Research tools

Free, no account — handy when you're working with MIA-606.

Reconstitution calculator Bac water, concentration & insulin-unit math Verify a COA Look up a report number against our corpus

TitrateLab PRO

Unlock the complete evidence trail

Pro members save studies and unlock the full evidence breakdown and vendor lab data.

Complete vendor lab histories
Every linked certificate on file
Batch-level purity and quantity detail
Thousands of community reviews

Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.

$14 monthly or $88/year

Create an account

TitrateLab

You must be 21 or older to enter.

TitrateLab provides research-use information on peptides for adults. Confirm your age to continue.

For research purposes only. Not for human consumption. By entering you agree to our Terms & Privacy.

MIA-606 studies and clinical research

GHRH-R antagonists MIA-602, MIA-606, and MIA-690 inhibit prostate cancer progression by inducing apoptosis and reducing proliferation.

Research tools